{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:23:05Z","timestamp":1792279385178,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["14095"],"award-info":[{"award-number":["14095"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Molecular Clinical Oncology Special Program","award":["9965"],"award-info":[{"award-number":["9965"]}]},{"name":"European Commission's 7th Framework Programme","award":["278706"],"award-info":[{"award-number":["278706"]}]},{"name":"MIUR PRIN","award":["2009WCNS5C_004"],"award-info":[{"award-number":["2009WCNS5C_004"]}]},{"name":"MIUR PRIN","award":["2010NECHBX"],"award-info":[{"award-number":["2010NECHBX"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clim.2017.11.014","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T22:31:32Z","timestamp":1511821892000},"page":"110-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial"],"prefix":"10.1016","volume":"191","author":[{"given":"Angelo","family":"Vacca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Melaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzurra","family":"Sportelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio G.","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Dammacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.11.014_bb0005","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.11.014_bb0010","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2017.11.014_bb0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2017.11.014_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02785839","article-title":"Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM)","volume":"16","author":"Kyrtsonis","year":"1999","journal-title":"Med. Oncol."},{"key":"10.1016\/j.clim.2017.11.014_bb0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2017.11.014_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2017.11.014_bb0035","first-page":"CD006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"4","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.clim.2017.11.014_bb0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"Blombery","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.clim.2017.11.014_bb0045","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1001\/jama.1990.03450240091046","volume":"264","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2017.11.014_bb0050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2017.11.014_bb0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2017.11.014_bb0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.all.0000246619.49494.41","article-title":"Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies","volume":"6","author":"Gardulf","year":"2006","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2017.11.014_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2017.11.014_bb0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Subcutaneous IgG Study Group, safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2017.11.014_bb0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.clim.2017.11.014_bb0080","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2017.11.014_bb0085","first-page":"9","article-title":"Ratio of involved\/uninvolved immunoglobulin quantification by Hevylite\u2122 assay: clinical and prognostic impact in multiple myeloma. Exp","volume":"1","author":"Koulieris","year":"2012","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.clim.2017.11.014_bb0090","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s10875-011-9588-5","article-title":"Efficacy and safety of subcutaneous vivaglobin\u00ae replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study","volume":"31","author":"Borte","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2017.11.014_bb0095","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","article-title":"Complications of multiple myeloma","volume":"21","author":"Blad\u00e9","year":"2007","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.clim.2017.11.014_bb0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.beha.2007.10.001","article-title":"Supportive care in multiple myeloma","volume":"20","author":"Ludwig","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.clim.2017.11.014_bb0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2017.11.014_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","article-title":"Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy","volume":"126","author":"Gardulf","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2017.11.014_bb0115","first-page":"105","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio","volume":"21","author":"Gardulf","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2017.11.014_bb0120","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2017.11.014_bb0125","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1399-3046.2012.01783.x","article-title":"Subcutaneous IgG replacement after pediatric SCT","volume":"16","author":"Sundin","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.clim.2017.11.014_bb0130","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.intimp.2013.02.021","article-title":"Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients","volume":"15","author":"Shankar","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2017.11.014_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2017.11.014_bb0140","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immunoglobulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus. Med. Rev."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617306332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617306332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T15:05:12Z","timestamp":1535209512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617306332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":28,"alternative-id":["S1521661617306332"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.11.014","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}